[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_5482 

# __Effectiveness of the anti-sars-cov-2 coatings__

## Articles mentionning the risk

* [Behzadinasab_surface_2020](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_414.md)

## Mitigations of this risk

* [Thorough testing and validation of coatings for long-term virucidal potency](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_7355.md)

## Name of the risk

Limited reduction in the transmission of SARS-CoV-2

## People affected by this risk

* [And regulators](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)
* [Manufacturers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_34.md)
* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_4672.md)

## Stakeholders who can mitigate this risk

* [Researchers and manufacturers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_4673.md)

## Technologies linked to the risk

* [Testing equipment for virucidal activity and durability of coatings](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_6687.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Lack of effective medical solutions](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_37.md)

